Examining the safety, efficacy, and patient acceptability of inhaled loxapine for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults.

Neuropsychiatr Dis Treat · 2019 · PMC6689540 · PMID 31496709

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

did not reach statistical significancep =0.06so close (0.05 < p ≤ 0.1)

A similar trend was noted in patients with bipolar disorder, however, it did not reach statistical significance (30 mins [95%CI 20.0–60.0 mins] vs 50 mins [95% CI 50.0–120.0 mins]) ( p =0.06).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.